Mycenax Biotech Overview
- Founded
-
2001
- Status
-
Public
- Employees
-
325
- Stock Symbol
-
4726
- Share Price
-
$1.26
- (As of Tuesday Closing)
Mycenax Biotech General Information
Description
Mycenax Biotech Inc is a Taiwan based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company's pipeline products include TuNEX(opinercept - lyophilizate), TuNEX(opinercept - solution), LusiNEX (tocilizumab), and Omalizumab.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
ROCO
Primary Office
- Research Zhunan Road
- 4th Floor, 50-7 Keyan Road
- Zhunan, Miaoli County 350-53
- Taiwan
+886 03 000 0000
Mycenax Biotech Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.26 | $1.25 | $1.12 - $1.84 | $195M | 155M | 4.72M | -$0.05 |
Mycenax Biotech Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 227,350 | 216,278 | 142,360 | 88,865 |
| Revenue | 26,624 | 27,707 | 22,603 | 12,648 |
| EBITDA | (652) | 2,953 | 5,590 | (3,527) |
| Net Income | (8,253) | (3,216) | 1,051 | (7,060) |
| Total Assets | 108,466 | 113,368 | 62,831 | 47,011 |
| Total Debt | 29,129 | 26,330 | 7,049 | 1,563 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Mycenax Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mycenax Biotech Patents
Mycenax Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-1253942-A1 | Cd40-binding apc-activating molecules | Inactive | 01-Feb-2000 | 000000000000 | |
| US-7820807-B2 | Can bind to and stimulate professional and non-professional human antigen-presenting cells, enhance the stimulatory effect of cd40l on cd40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells | Inactive | 01-Feb-2000 | 000000000000 | |
| US-20090311268-A1 | Can bind to and stimulate professional and non-professional human antigen-presenting cells, enhance the stimulatory effect of cd40l on cd40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells | Active | 01-Feb-2000 | 000000000000 | |
| US-20070098720-A1 | Bind to cell surface receptor, induce intracellular signal transduction, leading to activation of antigen presenting cells (apc) expressing cd40; cytotoxic effects, useful as antitumor agents | Active | 01-Feb-2000 | 000000000000 | |
| US-20010026932-A1 | Agonist anti-cd40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells; may be useful as antitumor agents | Active | 01-Feb-2000 | A61K39/39541 | 0 |
Mycenax Biotech Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Karen Wen | Founder & President |
Mycenax Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
